ATE165088T1 - Ungesättigte hydroxyalkylchinolinsäuren als leukotrien-antagonisten - Google Patents

Ungesättigte hydroxyalkylchinolinsäuren als leukotrien-antagonisten

Info

Publication number: ATE165088T1
Authority: AT; Austria
Prior art keywords: antagonists; leucotrien; hydroxyalkylquinolinic; unsaturated; acids
Prior art date: 1990-10-12

Application number

AT91309306T

Other languages

English (en)

Inventor

Michel L Belley

Serge Leger

Patrick Roy

Yi Bin Xiang

Marc Labelle

Daniel Guay

Original Assignee

Merck Frosst Canada Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1990-10-12

Filing date

1991-10-10

Publication date

1998-05-15

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27082671&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE165088(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1991-10-10 Application filed by Merck Frosst Canada Inc filed Critical Merck Frosst Canada Inc

1998-05-15 Application granted granted Critical

1998-05-15 Publication of ATE165088T1 publication Critical patent/ATE165088T1/de

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/22—Oxygen atoms attached in position 2 or 4
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/18—Halogen atoms or nitro radicals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/10—Expectorants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/24—Oxygen atoms attached in position 8

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Pulmonology (AREA)
Pain & Pain Management (AREA)
Ophthalmology & Optometry (AREA)
Rheumatology (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Immunology (AREA)
Endocrinology (AREA)
Reproductive Health (AREA)
Urology & Nephrology (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Plural Heterocyclic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Quinoline Compounds (AREA)
Agricultural Chemicals And Associated Chemicals (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Steroid Compounds (AREA)

AT91309306T 1990-10-12 1991-10-10 Ungesättigte hydroxyalkylchinolinsäuren als leukotrien-antagonisten ATE165088T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US59688790A	1990-10-12	1990-10-12
US74188891A	1991-08-08	1991-08-08

Publications (1)

Publication Number	Publication Date
ATE165088T1 true ATE165088T1 (de)	1998-05-15

Family

ID=27082671

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT91309306T ATE165088T1 (de)	1990-10-12	1991-10-10	Ungesättigte hydroxyalkylchinolinsäuren als leukotrien-antagonisten

Country Status (27)

Country	Link
EP (1)	EP0480717B1 (de)
JP (1)	JP2501385B2 (de)
KR (1)	KR100227716B1 (de)
CN (1)	CN1046711C (de)
AT (1)	ATE165088T1 (de)
CA (1)	CA2053209C (de)
CY (1)	CY2094B1 (de)
CZ (1)	CZ281274B6 (de)
DE (2)	DE69129257T2 (de)
DK (1)	DK0480717T3 (de)
ES (1)	ES2114882T3 (de)
FI (2)	FI104897B (de)
HK (1)	HK1027473A1 (de)
HR (1)	HRP930751B1 (de)
HU (2)	HU222344B1 (de)
IE (1)	IE913609A1 (de)
IL (3)	IL99726A (de)
LU (1)	LU90284I2 (de)
LV (1)	LV12187B (de)
MX (1)	MX9101551A (de)
NL (1)	NL990009I2 (de)
NO (1)	NO914004D0 (de)
NZ (1)	NZ240194A (de)
PT (1)	PT99213B (de)
SI (1)	SI9111647B (de)
SK (1)	SK279944B6 (de)
YU (1)	YU48742B (de)

Families Citing this family (91)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5270324A (en) *	1992-04-10	1993-12-14	Merck Frosst Canada, Inc.	Fluorinated hydroxyalkylquinoline acids as leukotriene antagonists
US5472964A (en) *	1992-12-22	1995-12-05	Merck Frosst Canada, Inc.	Diaryl 5,6-fused heterocyclic acids as leukotriene antagonists
CA2111372C (en) *	1992-12-22	2007-01-16	Robert N. Young	Diaryl 5,6-fusedheterocyclic acids as leukotriene antagonists
US5438141A (en) *	1993-05-21	1995-08-01	Merck Frosst Canada, Inc.	Heteroaryl and haloaryl quinoline derivatives of cyclopropaneacetic acid as leukotriene antagonists
ES2080656B1 (es) *	1993-07-19	1996-10-16	Merck Frosst Canada Inc	Acidos de hidroxialquilquinolina fluorados como antagonistas del leucotrieno.
CA2130723C (en) *	1993-09-03	2006-01-31	Wilhelm Quittmann	Process for preparing y-mercaptocarboxylic acid derivatives
DE4339724C1 (de) *	1993-11-22	1995-01-19	Siemens Ag	Gasarmatur
TW416948B (en) *	1993-12-28	2001-01-01	Merck & Co Inc	Process for the preparation of leukotriene antagonists
CA2145735A1 (en) *	1994-04-21	1995-10-22	Paul Hanselmann	Process for producing 5-oxaspiro[2.4]heptan-6-one and novel intermediate products obtained therein
US5523477A (en) *	1995-01-23	1996-06-04	Merck & Co., Inc.	Process for the preparation of 1-(thiomethyl)-cyclopropaneacetic acid
US5750539A (en) *	1995-06-07	1998-05-12	Merck Frosst Canada	Heteroaryl diol acids as leukotriene antagonists
US5714488A (en) *	1995-10-03	1998-02-03	Abbott Laboratories	Bis-heteroarylylmethoxyphenyl ketone derivatives as inhibitors of leukotriene biosynthesis
US5668150A (en) *	1996-07-26	1997-09-16	Abbott Laboratories	Non-symmetrical bis-heteroarylmethoxyphenylalkyl carboxylates as inhibitors of leukotriene biosynthesis
FR2751969B1 (fr)	1996-08-01	1998-12-04	Centre Nat Rech Scient	Composes activateurs du canal cftr, et compositions pharmaceutiques les contenant
US6262066B1 (en)	1998-07-27	2001-07-17	Schering Corporation	High affinity ligands for nociceptin receptor ORL-1
US6221880B1 (en)	1998-10-09	2001-04-24	Schering Corporation	Composition and method for treating allergic diseases
IT1320162B1 (it)	2000-02-09	2003-11-18	Rotta Research Lab	Derivati della tirosina ad attivita' anti leucotrienica, procedimentoper la loro preparazione e loro uso farmaceutico.
JP4308667B2 (ja) *	2002-02-06	2009-08-05	デルマーケミカルズインコーポレーテッド	１−（メルカプトメチル）−シクロプロパン酢酸の調製方法
CA2371048C (en)	2002-02-06	2011-01-04	Delmar Chemicals Inc.	Process for the preparation of 1-(mercaptomethyl)-cyclopropaneacetic acid
WO2003066598A1 (en) *	2002-02-07	2003-08-14	Dr. Reddy's Laboratories Ltd.	Novel anhydrous amorphous forms of montelukast sodium salt
WO2004108679A1 (en)	2003-06-06	2004-12-16	Morepen Laboratories Limited	An improved method for the preparation of montelukast acid and sodium salt thereof in amorphous form
PT1678139E (pt)	2003-10-10	2011-11-28	Synhton B V	Montelucaste em estado sólido
US20070225325A1 (en) *	2004-01-28	2007-09-27	Pliva-Istrazivanje I Razvoj D.O.O.	Solid Forms of Montelukast Acid
EP1708708A1 (de) *	2004-01-30	2006-10-11	Teva Pharmaceutical Industries Ltd.	Montelukast-freie säure-polymorphen
EP1760077A1 (de) *	2004-01-30	2007-03-07	Teva Pharmaceutical Industries Ltd.	Polymorphe Formen vonMontelukast freie Säure
WO2005074893A1 (en)	2004-02-03	2005-08-18	Chemagis Ltd.	Stable amorphous forms of montelukast sodium
MXPA06012220A (es) *	2004-04-21	2007-07-18	Teva Pharma	Procesos para preparar sodio de montelukast.
US7829716B2 (en)	2004-04-30	2010-11-09	Synthon Pharmaceuticals, Inc.	Process for making montelukast and intermediates therefor
US7501517B2 (en)	2004-04-30	2009-03-10	Synthon Ip, Inc.	Process for making montelukast and intermediates therefor
ATE539061T1 (de)	2004-07-19	2012-01-15	Matrix Lab Ltd	2-ä(3s)-ä3-ä(2e)-(7-chlorchinolin-2- yl)ethenylüphenylü-3- halogenpropylübenzoesäuremethylester
DE602004031678D1 (de) *	2004-07-19	2011-04-14	Matrix Lab Ltd	Verfahren zur herstellung von montelukast und salzen davon
WO2006008562A1 (en) *	2004-07-23	2006-01-26	Pliva-Istrazivanje I Razvoj D.O.O.	Process
WO2006021974A1 (en) *	2004-08-23	2006-03-02	Morepen Laboratories Limited	A process for synthesizing diol (viii)-an intermediate of montelukast sodium
PL205637B1 (pl) *	2004-10-22	2010-05-31	Inst Farmaceutyczny	Sposób wytwarzania kwasu (R,E)-(1-{1-{3-[2-(7-chlorochinolin-2-ylo)etenylo]fenylo}-3-[2-(1-hydroksy-1-metyloetylo)fenylo] propylosulfanylometylo}cyklopropylo)octowego i/lub jego farmaceutycznie dopuszczalnych soli
CA2589936A1 (en) *	2004-11-30	2006-06-08	Medichem S.A.	New process for the preparation of a leukotriene antagonist
WO2006131782A1 (en) *	2005-06-07	2006-12-14	Glade Organics Private Limited	Process for the manufacture of methyl-2-(3-(2-(7-chloro-2-quinolinyl-ethenyl)-phenyl)-3-oxopropyl) benzoate
KR20090015186A (ko)	2005-07-05	2009-02-11	테바 파마슈티컬 인더스트리즈 리미티드	몬테루카스트의 정제
US20070161796A1 (en) *	2005-11-16	2007-07-12	Ilan Kor-Sade	Drying methods of montelukast sodium by azeotropic removal of the solvent
AR057908A1 (es)	2005-11-18	2007-12-26	Synthon Bv	Proceso para preparar montelukast e intermediarios del mismo
WO2007069261A1 (en)	2005-12-13	2007-06-21	Msn Laboratories Limited	An improved process for the preparation of montelukast and its pharmaceutically acceptable salts
US7572930B2 (en)	2006-02-02	2009-08-11	Chemagis Ltd.	Process for preparing 1-(mercaptomethyl)cyclopropaneacetic acid, a useful intermediate in the preparation of montelukast and salts thereof
US7528254B2 (en)	2006-02-27	2009-05-05	Chemagis Ltd.	Process for preparing montelukast and salts thereof
EP2004609A2 (de) *	2006-03-06	2008-12-24	Farmaprojects, S.A.	Verfahren zur herstellung eines leukotrienantagonisten
EP1996552A1 (de)	2006-03-17	2008-12-03	Synthon B.V.	Montelukast-amantadin-salz
US20090281323A1 (en)	2006-04-12	2009-11-12	Glade Organics Private Limited	Process for the manufacture of montelukast sodium
US20060223999A1 (en) *	2006-05-10	2006-10-05	Chemagis Ltd.	Process for preparing montelukast and precursors thereof
GB0614485D0 (en) *	2006-07-21	2006-09-27	Pliva Istrazivanje I Razvoj D	Process
EP1886998A1 (de) *	2006-08-09	2008-02-13	Esteve Quimica, S.A.	Verfahren zur Reinigung von Montelukast und dessen Aminesalzen
GB0618703D0 (en) *	2006-09-22	2006-11-01	Almac Sciences Ltd	Synthesis of leikotriene compounds
US7700776B2 (en)	2006-10-24	2010-04-20	Formosa Laboratories, Inc.	Compounds and preparation for montelukast sodium
US8115004B2 (en)	2006-11-20	2012-02-14	Msn Laboratories Limited	Process for pure montelukast sodium through pure intermediates as well as amine salts
US7271268B1 (en)	2006-12-22	2007-09-18	Formosa Laboratories Inc.	Process for preparation of [1-(mercaptomethyl)cyclopropyl]acetic acid and related derivatives
EP1958936A1 (de) *	2007-02-14	2008-08-20	Inke, S.A.	Verfahren zur Gewinnung von Montelukast
EP1988079A1 (de) *	2007-04-25	2008-11-05	Lonza Ag	Verfahren zur Herstellung optisch aktiver Ethenylphenylalkohole
PL205444B1 (pl)	2007-05-02	2010-04-30	Zak & Lstrok Ady Farmaceutyczn	Sposób wytwarzania soli sodowej kwasu 1-(((1(R)-(3-(2-(7--chloro-2- chinolinylo)-etenylo)fenylo)-3-(2-(1-hydroksy-1- metyloetylo)fenylo)propylo)sulfanylo)metylo)-cyklopropanooctowego
ES2320077B1 (es)	2007-07-31	2010-02-26	Moehs Iberica, S.L.	Proceso de preparacion de un antagonista de leucotrienos y de un intermedio del mismo.
KR101072896B1 (ko)	2007-10-09	2011-10-17	한미홀딩스 주식회사	이온성 액체 매개체를 이용한 몬테루카스트산의 제조 방법
EP2053043A1 (de)	2007-10-26	2009-04-29	Inke, S.A.	Montelukast-Kristallsalz
DE102007061630B4 (de)	2007-12-20	2013-07-04	Formosa Laboratories, Inc.	Neue Verbindungen und Herstellung von Montelukast-Natrium
CN101817818B (zh) *	2008-03-06	2011-10-26	台耀化学股份有限公司	一种用于制备孟鲁司特钠的化合物
EP2288595B1 (de)	2008-05-26	2016-11-02	Laurus Labs Private Limited	Verbessertes verfahren zur herstellung von montelukast und salzen daraus
TR200806298A2 (tr)	2008-08-22	2010-03-22	Bi̇lgi̇ç Mahmut	Farmasötik formülasyon
KR101123292B1 (ko) *	2008-09-26	2012-03-19	주식회사 엘지생명과학	몬테루카스트 나트륨염의 제조방법
WO2010064109A2 (en)	2008-12-02	2010-06-10	Mayuka Labs Private Limited	An improved process for the preparation of montelukast sodium and its intermediates
WO2010107404A1 (en)	2009-03-16	2010-09-23	Mahmut Bilgic	Stable pharmaceutical combinations
TW201111392A (en)	2009-06-16	2011-04-01	Schering Corp	Novel [3,2-c] heteroaryl steroids as glucocorticoid receptor agonists, compositions and uses thereof
WO2011004298A1 (en)	2009-07-09	2011-01-13	Alembic Limited	Montelukast hexamethylenediamine salt and its use for the preparation of montelukast sodium
EP2287154A1 (de)	2009-07-14	2011-02-23	KRKA, D.D., Novo Mesto	Effiziente Synthese zur Herstellung von Montelukast
CN101638381B (zh) *	2009-09-02	2012-08-29	鲁南制药集团股份有限公司	孟鲁司特钠中间体的合成方法
WO2011042416A1 (en)	2009-10-09	2011-04-14	Dsm Ip Assets B.V.	Sythesis of optically active intermediate for the preparation of montelukast
EP2516401A1 (de)	2009-12-23	2012-10-31	Pharmathen S.A.	Verbessertes verfahren zur herstellung von montelukast und salzen daraus
EP2552892A1 (de)	2010-03-31	2013-02-06	KRKA, D.D., Novo Mesto	Effiziente synthese zur herstellung von montelukast und neue kristalline form von zwischenprodukten darin
KR100990046B1 (ko) *	2010-07-30	2010-10-26	동국제약 주식회사	신규한 몬테루카스트 4-할로 벤질아민염 및 이를 이용한 몬테루카스트 나트륨염의 제조방법
HUP1000425A2 (en)	2010-08-11	2012-03-28	Richter Gedeon Nyrt	Process for the production of montelukast sodium
TR201009394A2 (tr)	2010-11-11	2012-06-21	Bi̇lgi̇ç Mahmut	Geliştirilmiş montelukast formülasyonları.
TR201009398A2 (tr)	2010-11-11	2012-05-21	Bi̇lgi̇ç Mahmut	Fiziksel özellikleri geliştirilmiş tablet formülasyonları
US8471030B2 (en)	2010-12-06	2013-06-25	Orochem Technologies Inc.	Purification of montelukast using simulated moving bed
EP2502910A1 (de)	2011-03-15	2012-09-26	Laboratorios Lesvi, S.L.	Camphersulfonsalz eines Montelukastschlüssels Zwischenprodukt
CN102690229B (zh) *	2011-03-23	2016-06-08	上海相辉医药科技有限公司	一种孟鲁司特钠的合成及其制备中间体
WO2013051024A2 (en) *	2011-07-26	2013-04-11	Sun Pharma Advanced Research Company Ltd.	Cysteinyl leukotriene antagonists
WO2013077829A1 (en)	2011-11-21	2013-05-30	Mahmut Bilgic	Water-soluble pharmaceutical granules
WO2014118796A1 (en)	2013-01-31	2014-08-07	Melody Healthcare Pvt. Ltd.	An in-situ process for the preparation of highly pure montelukast sodium
CN104109122B (zh) *	2013-04-16	2017-03-29	浙江奥翔药业股份有限公司	用于合成孟鲁司特的中间体化合物及其制备方法
CN104370810B (zh) *	2013-08-13	2016-10-05	天津汉瑞药业有限公司	孟鲁司特钠化合物
CN103554017B (zh) *	2013-10-25	2014-12-17	河北序能生物技术有限公司	一种孟鲁司特钠手性中间体的制备方法
CN103936671B (zh) *	2014-05-06	2015-10-28	启东东岳药业有限公司	孟鲁司特钠中间体的制备方法
CN105294556A (zh) *	2014-06-06	2016-02-03	上海迪赛诺化学制药有限公司	一种制备孟鲁司特酸的方法
CN105085391B (zh) *	2015-06-10	2017-08-22	广东默泰同创医药科技有限公司	用作白三烯受体拮抗剂的环丙基不饱和喹啉化合物及应用
CN105363019B (zh) *	2015-12-16	2018-04-24	新乡医学院第一附属医院	一种治疗溶血性贫血的环孢素组合物及其应用
CN108530355B (zh) *	2018-06-08	2019-09-10	福州华博立乐新材料科技有限公司	一种3-[2-(7-氯-2-喹啉基)乙烯基]苯甲醛的合成方法
CN108435257A (zh) *	2018-06-08	2018-08-24	福州华博立乐新材料科技有限公司	一种用于合成3-[2-(7-氯-2-喹啉基)乙烯基]苯甲醛的催化剂

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IE861607L (en) *	1985-06-18	1986-12-18	Bunce Roger A	2-substituted quinolines
IE59889B1 (en) *	1986-02-14	1994-04-20	Merck Frosst Canada Inc	2-substituted quinoline dioic acids
US4851409A (en) *	1986-02-14	1989-07-25	Merck Frosst Canada Inc.	2-substituted quinoline dioic acids and pharmaceutical compositions
JPS62258362A (ja) *	1986-05-02	1987-11-10	Terumo Corp	アミド誘導体およびこれを含有する５−リポキシゲナ−ゼ作用阻害剤
EP0271287A3 (de) *	1986-12-11	1990-06-13	Merck Frosst Canada Inc.	Chinolindicarbonsäuren und ihre Amide
IL88433A0 (en) *	1987-11-25	1989-06-30	Merck Frosst Canada Inc	Diarylstyrylquinoline diacids and pharmaceutical compositions containing them
NZ233752A (en) *	1989-05-24	1993-05-26	Merck Frosst Canada Inc	Substituted quinoline derivatives, preparation and pharmaceutical compositions thereof
WO1990015801A1 (en) *	1989-06-22	1990-12-27	Pfizer Inc.	Substituted sulfonamides and related compounds in the treatment of asthma, arthritis and related diseases

1991
- 1991-10-10 EP EP91309306A patent/EP0480717B1/de not_active Expired - Lifetime
- 1991-10-10 AT AT91309306T patent/ATE165088T1/de active
- 1991-10-10 DE DE69129257T patent/DE69129257T2/de not_active Expired - Lifetime
- 1991-10-10 HU HU9103217A patent/HU222344B1/hu active IP Right Grant
- 1991-10-10 CA CA002053209A patent/CA2053209C/en not_active Expired - Lifetime
- 1991-10-10 ES ES91309306T patent/ES2114882T3/es not_active Expired - Lifetime
- 1991-10-10 DK DK91309306T patent/DK0480717T3/da active
- 1991-10-10 DE DE1998175039 patent/DE19875039I2/de active Active
- 1991-10-11 MX MX9101551A patent/MX9101551A/es unknown
- 1991-10-11 CZ CS913095A patent/CZ281274B6/cs not_active IP Right Cessation
- 1991-10-11 SI SI9111647A patent/SI9111647B/sl unknown
- 1991-10-11 SK SK3095-91A patent/SK279944B6/sk not_active IP Right Cessation
- 1991-10-11 NZ NZ240194A patent/NZ240194A/en not_active IP Right Cessation
- 1991-10-11 PT PT99213A patent/PT99213B/pt not_active IP Right Cessation
- 1991-10-11 NO NO914004A patent/NO914004D0/no unknown
- 1991-10-11 FI FI914796A patent/FI104897B/fi not_active IP Right Cessation
- 1991-10-11 YU YU164791A patent/YU48742B/sh unknown
- 1991-10-11 CN CN91110816A patent/CN1046711C/zh not_active Expired - Lifetime
- 1991-10-12 KR KR1019910017953A patent/KR100227716B1/ko not_active IP Right Cessation
- 1991-10-13 IL IL99726A patent/IL99726A/en not_active IP Right Cessation
- 1991-10-13 IL IL11714791A patent/IL117147A/xx not_active IP Right Cessation
- 1991-10-13 IL IL11714796A patent/IL117147A0/xx unknown
- 1991-10-14 JP JP3331110A patent/JP2501385B2/ja not_active Expired - Lifetime
- 1991-10-16 IE IE360991A patent/IE913609A1/en active Protection Beyond IP Right Term
1993
- 1993-04-02 HR HR930751A patent/HRP930751B1/xx not_active IP Right Cessation
1995
- 1995-06-09 HU HU95P/P00178P patent/HU211294A9/hu unknown
1998
- 1998-07-14 HK HK98109133A patent/HK1027473A1/xx not_active IP Right Cessation
- 1998-07-17 CY CY9800016A patent/CY2094B1/xx unknown
- 1998-07-23 LV LVP-98-153A patent/LV12187B/en unknown
- 1998-09-02 LU LU90284C patent/LU90284I2/fr unknown
1999
- 1999-04-01 NL NL990009C patent/NL990009I2/nl unknown
2000
- 2000-02-07 FI FI20000250A patent/FI20000250A/fi unknown

Also Published As

Publication number	Publication date
AU639610B2 (en)	1993-07-29
FI914796A (fi)	1992-04-13
FI914796A0 (fi)	1991-10-11
LU90284I2 (fr)	1998-11-03
SI9111647B (en)	2001-06-30
KR100227716B1 (ko)	1999-11-01
LV12187B (en)	1999-02-20
ES2114882T3 (es)	1998-06-16
CZ281274B6 (cs)	1996-08-14
IL99726A (en)	1998-02-22
JPH05105665A (ja)	1993-04-27
MX9101551A (es)	1992-06-05
JP2501385B2 (ja)	1996-05-29
EP0480717A1 (de)	1992-04-15
NO914004D0 (no)	1991-10-11
HU222344B1 (hu)	2003-06-28
DE19875039I2 (de)	2003-05-22
HK1027473A1 (en)	2001-01-12
IL117147A0 (en)	1996-06-18
HRP930751A2 (en)	1995-06-30
YU164791A (sh)	1994-04-05
FI20000250A (fi)	2000-02-07
CN1061407A (zh)	1992-05-27
DK0480717T3 (da)	1999-02-08
NL990009I2 (nl)	1999-07-01
CY2094B1 (en)	2002-04-05
FI104897B (fi)	2000-04-28
LV12187A (lv)	1998-12-20
CA2053209C (en)	1998-12-08
IE913609A1 (en)	1992-04-22
SI9111647A (en)	1997-12-31
IL99726A0 (en)	1992-08-18
SK279944B6 (sk)	1999-06-11
EP0480717B1 (de)	1998-04-15
NZ240194A (en)	1995-03-28
HRP930751B1 (en)	2000-06-30
CS309591A3 (en)	1992-04-15
HU913217D0 (en)	1992-01-28
YU48742B (sh)	1999-09-27
HUT61981A (en)	1993-03-29
KR920008006A (ko)	1992-05-27
HU211294A9 (en)	1995-11-28
NL990009I1 (nl)	1999-06-01
PT99213B (pt)	1999-01-29
CN1046711C (zh)	1999-11-24
CA2053209A1 (en)	1992-04-13
PT99213A (pt)	1992-09-30
DE69129257T2 (de)	1998-11-05
IL117147A (en)	2000-10-31
AU8579491A (en)	1992-04-16
DE69129257D1 (de)	1998-05-20

Publication	Publication Date	Title
DE69129257T2 (de)	1998-11-05	Ungesättigte Hydroxyalkylchinolinsäuren als Leukotrien-Antagonisten
MX9302033A (es)	1994-07-29	Acidos de hidroxialquilquinolina fluorados como antagonistas de leucotrieno.
NO952495D0 (no)	1995-06-21	Diaryl-5,6-kondenserte heterosykliske syrer som leukotrienantagonister
EP0480708A3 (en)	1992-05-20	Hydroxyalkylquinoline ether acids as leukotriene antagonists